<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265642</url>
  </required_header>
  <id_info>
    <org_study_id>2005-006027-37</org_study_id>
    <secondary_id>ANRS HC 19 Fibrosar</secondary_id>
    <nct_id>NCT00265642</nct_id>
  </id_info>
  <brief_title>Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C</brief_title>
  <acronym>Fibrosar</acronym>
  <official_title>Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy of irbesartan on the progression of
      liver fibrosis in adult patients with chronic hepatitis C.

      The expected total enrollment is 200 patients. Patients who meet the study criteria and
      accept to participate at this study will take by day one tablet of 150 mg of treatment
      (irbesartan or placebo) during two years. The assessment of efficacy will be make by
      evaluation of area of liver fibrosis and blood markers of liver fibrosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of several studies suggests than the AT1 receptor antagonists of angiotensin II
      have inhibitory effects on TGF-beta 1 production and can limit the progression of liver
      fibrosis.

      Therefore, the angiotensin II could be another mediator of the synthesis of the
      extra-cellular matrix at the hepatic level, opening new perspectives with the antagonists of
      angiotensin II receptors drugs (ARA2/sartans).

      This study is a randomized, double blind, multi-center, parallel assignment, and efficacy
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of liver fibrosis changes by measurement of area of porto-septal fibrosis (morphometry)at M24</measure>
    <time_frame>at M24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of liver fibrosis changes at M24 by non-invasive tests ((blood test mainly and also elastometry)</measure>
    <time_frame>at M24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>group verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Irbesartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>one tablet of 150 mg/d during 2 years</description>
    <arm_group_label>group verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one tablet per day during 2 years</description>
    <arm_group_label>group placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 75 years

          -  liver biopsy performed (less 18 month before inclusion), fibrosis score F2,F3 or F3+
             in Metavir classification,

          -  patients without antiviral therapy

          -  contraindication to anti viral treatment

          -  non responders or relapsers patients to past antiviral treatment

        Exclusion Criteria:

          -  hepatocellular carcinoma

          -  HIV

          -  alcool abuser

          -  cirrhosis

          -  anti-fibrotic treatment

          -  pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Cales, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Angers, Service d'hépato-gastroentérologie, 49933 Angers Cedex 09</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrice Carrat, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Inserm U707 France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers, Service d'hépato-gastroentérologie</name>
      <address>
        <city>Angers</city>
        <zip>49933 cedex 09</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>irbesartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

